drugset / Trial / NCT00172172
Calcium Supplementation in Postmenopausal Women
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is evaluating the effects of calcium supplementation on the efficacy and safety of recombinant parathyroid hormone (ALX1-11) in postmenopausal women with osteoporosis. The primary objective of this clinical study is to evaluate whether increases in bone mineral density (BMD) for subjects treated with ALX1-11 and receiving no calcium supplementation are less than increases in BMD observed for subjects treated with ALX1-11 and receiving calcium supplementation.
Timeline
- Start
- 2004-01-10
- Primary completion
- 2005-03-11
- Completion
- 2005-03-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Calcium carbonate | Other / unclassified | 700 mg | Oral |
| Subject | Parathyroid Hormone | Protein / enzyme biologic | 100 ug | Subcutaneous |